| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.
|
N Engl J Med
|
1993
|
102.56
|
|
2
|
Effects of insulin in relatives of patients with type 1 diabetes mellitus.
|
N Engl J Med
|
2002
|
7.00
|
|
3
|
Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
|
Ann Intern Med
|
1998
|
6.13
|
|
4
|
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
|
N Engl J Med
|
1994
|
5.28
|
|
5
|
Insulin prophylaxis in individuals at high risk of type I diabetes.
|
Lancet
|
1993
|
2.63
|
|
6
|
Banting lecture 1990. Beta-cells in type II diabetes mellitus.
|
Diabetes
|
1991
|
2.45
|
|
7
|
Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease.
|
Diabetes
|
1993
|
2.15
|
|
8
|
Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
|
Diabetes Care
|
1997
|
1.76
|
|
9
|
Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation.
|
Lancet
|
1993
|
1.68
|
|
10
|
Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy.
|
Diabetes
|
1990
|
1.51
|
|
11
|
Immunogenetic and clinical characterization of slowly progressive IDDM.
|
Diabetes Care
|
1993
|
1.44
|
|
12
|
Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview.
|
Diabetologia
|
1992
|
1.38
|
|
13
|
Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency.
|
Diabet Med
|
1994
|
1.36
|
|
14
|
Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis.
|
Diabetes
|
1986
|
1.26
|
|
15
|
The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography.
|
Diabetes Care
|
1995
|
1.18
|
|
16
|
Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus.
|
Diabetologia
|
1987
|
1.18
|
|
17
|
Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
|
Diabetologia
|
1996
|
1.17
|
|
18
|
Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals.
|
Diabetologia
|
1985
|
1.08
|
|
19
|
Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type.
|
J Clin Invest
|
1993
|
1.07
|
|
20
|
Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus.
|
Diabetes
|
1992
|
1.06
|
|
21
|
Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients.
|
Diabetes
|
1999
|
1.02
|
|
22
|
Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes.
|
Diabetes
|
1988
|
1.00
|
|
23
|
Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.
|
Diabetes
|
1996
|
0.97
|
|
24
|
Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes.
|
Metabolism
|
2001
|
0.92
|
|
25
|
Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy.
|
Diabetes
|
1995
|
0.89
|
|
26
|
Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus.
|
Ann N Y Acad Sci
|
2002
|
0.89
|
|
27
|
The functional state of the beta cell modulates IL-1 and TNF-induced cytotoxicity.
|
Lymphokine Cytokine Res
|
1993
|
0.85
|
|
28
|
Functional state of the beta cell affects expression of both forms of glutamic acid decarboxylase.
|
Pancreas
|
1994
|
0.84
|
|
29
|
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.
|
Clin Exp Immunol
|
2013
|
0.84
|
|
30
|
Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes.
|
Diabetes
|
1987
|
0.84
|
|
31
|
Maleness as risk factor for slowly progressive IDDM.
|
Diabetes Care
|
1989
|
0.83
|
|
32
|
Relationships among islet cell antibodies, residual beta-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay.
|
Metabolism
|
1990
|
0.82
|
|
33
|
Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults.
|
Diabetologia
|
1984
|
0.82
|
|
34
|
Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM--the clinical characteristics and pathogenesis of the syndrome.
|
Diabetes Res Clin Pract
|
1994
|
0.79
|
|
35
|
Predictive value of insulin autoantibodies for further progression of beta cell dysfunction in non-insulin-dependent diabetics.
|
Diabetes Res
|
1988
|
0.77
|